Quick Search:

uzh logo
Browse by:
bullet
bullet
bullet
bullet

Zurich Open Repository and Archive

Permanent URL to this publication: http://dx.doi.org/10.5167/uzh-4786

Ganter, M T; Schmuck, S; Hamiel, C R; Wischmeyer, P E; Heule, D; Zollinger, A; Hofer, C K (2008). Monitoring recombinant factor VIIa treatment: efficacy depends on high levels of fibrinogen in a model of severe dilutional coagulopathy. Journal of Cardiothoracic and Vascular Anesthesia, 22(5):675-680.

[img]
Preview
Accepted Version
PDF
1MB

View at publisher

Abstract

OBJECTIVES: Recombinant activated factor VII (rFVIIa) is increasingly being given to treat massive bleeding. However, there is no clear guidance on which patients are suitable for treatment and how the effects of treatment should be monitored. The aim of this in vitro study was to assess the coagulation status of severely hemodiluted blood samples before and after treatment with therapeutic doses of rFVIIa and/or fibrinogen with 2 viscoelastic point-of-care coagulation analyzers: ROTEM (Pentapharm GmbH, Munich, Germany) and Sonoclot (Sienco Inc, Arvada, CO). DESIGN: Laboratory study. SETTING: Research coagulation laboratory. PARTICIPANTS: Ten healthy male volunteers without hereditary or acquired coagulation disorders. INTERVENTIONS: Blood samples were obtained. After severe hemodilution with albumin 5%, therapeutic doses of rFVIIa and/or fibrinogen were added, and the coagulation status was assessed with new 1:1,000 diluted tissue factor-activated tests from ROTEM and Sonoclot. MEASUREMENTS AND MAIN RESULTS: The administration of therapeutic doses of rFVIIa to hemodiluted samples shortened the initiation phase of coagulation only. Isolated fibrinogen administration to physiologic levels improved both the initiation of coagulation as well as clot formation and strength. Combined fibrinogen and rFVIIa administration further improved both effects. CONCLUSIONS: ROTEM and Sonoclot were able to monitor the effects of rFVIIa and fibrinogen administration with 1:1,000 diluted tissue factor-activated tests. The efficacy of rFVIIa was largely dependent on the presence of high levels of fibrinogen in reversing this severe dilutional coagulopathy.

Citations

11 citations in Web of Science®
12 citations in Scopus®
Google Scholar™

Altmetrics

Downloads

238 downloads since deposited on 28 Oct 2008
11 downloads since 12 months

Detailed statistics

Additional indexing

Item Type:Journal Article, refereed, original work
Communities & Collections:04 Faculty of Medicine > University Hospital Zurich > Institute of Anesthesiology
DDC:610 Medicine & health
Language:English
Date:2008
Deposited On:28 Oct 2008 15:56
Last Modified:27 Nov 2013 17:16
Publisher:Elsevier
ISSN:1053-0770
Publisher DOI:10.1053/j.jvca.2008.01.017
PubMed ID:18922422

Users (please log in): suggest update or correction for this item

Repository Staff Only: item control page